Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Stock Information for Kaival Brands Innovations Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kaival Brands Innovations Group Inc.

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
Mesabi Trust Press Release
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Mesoblast to Host R&D Day on April 8, 2026
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.